AstraZeneca PLC (LON:AZN) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of AstraZeneca PLC (LON:AZN) have earned an average rating of “Moderate Buy” from the six ratings firms that are presently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is GBX 6,303.50 ($83.62).

Several equities analysts have recently issued reports on the stock. Berenberg Bank reaffirmed a “buy” rating and issued a GBX 140 ($1.86) price objective on shares of AstraZeneca in a research note on Wednesday, March 26th. JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a report on Wednesday, February 19th. Finally, Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Tuesday, April 29th.

AstraZeneca Stock Performance

Shares of LON AZN opened at £100.68 ($133.56) on Friday. The company has a current ratio of 0.93, a quick ratio of 0.59 and a debt-to-equity ratio of 73.83. The stock has a 50 day simple moving average of £107.81 and a 200-day simple moving average of £108.82. The company has a market cap of £193.71 billion, a PE ratio of 27.60, a P/E/G ratio of 0.86 and a beta of 0.17. AstraZeneca has a 12-month low of GBX 9,573.51 ($127.00) and a 12-month high of £133.88 ($177.61).

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.